Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Antitumor Therapeutics
8%
B16F10 Melanoma
8%
C57BL
8%
CD4+ Regulatory T Cells
8%
CD4+ T
8%
CD8+
16%
Clinical Activity
8%
Day 14
8%
Gp100
8%
High Dose
16%
Immunogenic
8%
Immunotherapy Agent
8%
Low-dose interleukin-2
100%
Melanoma
100%
Melanoma Cells
8%
Metastatic Melanoma
8%
Mouse Model
100%
Natural Killer Cells
8%
Objective Response
8%
Patient Cohort
8%
Placebo
8%
Placebo Treatment
8%
Recombinant interleukin-2
100%
Renal Cell Carcinoma
8%
Therapeutic Efficacy
8%
Therapeutic Response
100%
Treg
8%
Tumor
25%
Tumor Growth
25%
Tumor Immunity
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adjuvant
8%
C57BL 6 Mouse
8%
CD8 Antigen
16%
Clinical Study
16%
Glycoprotein Gp 100
8%
Immunotherapy
8%
Interleukin 2
100%
Low Drug Dose
100%
Melanoma
100%
Metastatic Melanoma
8%
Mouse Model
100%
Neoplasm
100%
Placebo
16%
Recombinant Interleukin 2
100%
Renal Cell Carcinoma
8%
Tumor Growth
25%
Immunology and Microbiology
Adjuvant
8%
C57BL 6 Mouse
8%
CD4
8%
CD8
8%
Cytotoxic T-Cell
8%
Drug Megadose
16%
Immunotherapy
8%
Interleukin 2
100%
Low Drug Dose
100%
Mouse Model
100%
Natural Killer Cell
8%
Recombinant Interleukin 2
100%
Regulatory T Cell
16%
T-Helper Cell
8%
Tumor Immunity
100%
Biochemistry, Genetics and Molecular Biology
C57BL 6 Mouse
7%
CD4
15%
CD8
15%
Clinical Study
15%
Drug Megadose
15%
Interleukin 2
100%
Low Drug Dose
100%
Mouse Model
100%
Natural Killer Cell
7%
Regulatory T Cell
15%
T Cell
7%
Tumor Immunity
100%
Tumor Progression
23%